CytomX Therapeutics, Inc.
CTMX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001501989
No open-market purchases or sales by CytomX Therapeutics, Inc. insiders were filed in the last 90 days; 178 institutions reported holding it in 13F filings for Q2 2026, worth $799.0M in total; no superinvestor holds it.
13F holders, Q3 2025
Institutional positions in CytomX Therapeutics, Inc. as of Sep 30, 2025. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 103
- +20 vs. Q2 2025
- Shares held
- 137.4M
- +4.12M (+3.1%) vs. Q2 2025
- Total value
- $438.4M
- +$135.8M (+44.9%) vs. Q2 2025
- New holders
- 32
- 29 more added
- Sold out
- 12
- 25 more reduced
Compare with Q2 2025: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting CTMX on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 178 | $799.0M |
| Q1 2026 | 179 | $911.2M |
| Q4 2025 | 122 | $613.9M |
| Q3 2025 | 103 | $438.4M |
| Q2 2025 | 83 | $302.6M |
| Q1 2025 | 66 | $28.8M |
| Q4 2024 | 70 | $48.1M |
| Q3 2024 | 69 | $60.4M |
| Q2 2024 | 74 | $61.9M |
| Q1 2024 | 88 | $97.1M |
| Q4 2023 | 68 | $50.6M |
| Q3 2023 | 62 | $41.8M |
| Q2 2023 | 67 | $58.7M |
| Q1 2023 | 76 | $53.7M |
| Q4 2022 | 81 | $57.5M |
| Q3 2022 | 84 | $52.6M |
| Q2 2022 | 99 | $83.4M |
| Q1 2022 | 119 | $143.4M |
| Q4 2021 | 110 | $236.5M |
| Q3 2021 | 114 | $274.8M |
| Q2 2021 | 122 | $358.9M |
| Q1 2021 | 126 | $422.2M |
Institutions, Q3 2025
Shares, value and share of portfolio for each institution holding CytomX Therapeutics, Inc.; share changes are against Q2 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Tang Capital Management LLC | 11,065,662 | $35.3M | 1.36% | 00.0% | Unchanged |
| FMR LLC | 15,396,200 | $49.1M | 0.00% | +6,157,332+66.6% | Added |
| VR Adviser, LLC | 15,561,500 | $49.6M | 2.79% | +1,591,618+11.4% | Added |
| Franklin Resources Inc | 0 | $0 | 0.00% | −5,769,230−100.0% | Sold out |
| Fairmount Funds Management LLC | 0 | $0 | 0.00% | −3,896,582−100.0% | Sold out |
| Soleus Capital Management, L.P. | 0 | $0 | 0.00% | −1,304,300−100.0% | Sold out |
| Readystate Asset Management LP | 0 | $0 | 0.00% | −844,643−100.0% | Sold out |
| EAM Investors, LLC | 0 | $0 | 0.00% | −254,580−100.0% | Sold out |
| Bridgeway Capital Management, LLC | 0 | $0 | 0.00% | −126,000−100.0% | Sold out |
| Commonwealth Equity Services, LLC | 0 | $0 | 0.00% | −53,243−100.0% | Sold out |
| Bayesian Capital Management, LP | 0 | $0 | 0.00% | −50,117−100.0% | Sold out |
| Two Sigma Securities, LLC | 0 | $0 | 0.00% | −47,311−100.0% | Sold out |
| Lazard Asset Management LLC | 0 | $0 | 0.00% | −43,316−100.0% | Sold out |
| Virtu Financial LLC | 0 | $0 | 0.00% | −35,136−100.0% | Sold out |
| Federated Hermes, Inc. | 0 | $0 | 0.00% | −398−100.0% | Sold out |